ASCO GU 2026: Positive additive effect of luxdegalutamide + with 177Lu-PSMA-617 for PSMA-positive mCRPC

Luxdegalutamide, a novel PROTAC drug, has shown promising positive effects and good tolerability in phase I/II studies in the treatment of patients with mCRPC, a patient group with a poor prognosis and rapid disease progression. At ASCO GU 2026, Daniel Petrylak presented a study designed to evaluate the efficacy, safety, and tolerability of luxdegalutamide in combination with 177Lu-PSMA-617, using two oral formulations, compared with 177Lu-PSMA-617 monotherapy in patients with PSMA-positive mCRPC.